(Bloomberg) -- When the chairman of the foundation that controls Danish weight-loss drug giant Novo Nordisk A/S dismissed its chief executive and then much of the board, it upended the country’s ...

Genesis’ proprietary foundation model – Pearl – outperforms frontier models, including AlphaFold 3, on key benchmarks that predict utility in real-world drug discovery Pearl’s performance improved ...